 Teri Schreiner
Concepts (268)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 46 | 2026 | 489 | 6.450 |
Why?
| | Cognitive Dysfunction | 5 | 2025 | 468 | 1.090 |
Why?
| | Neuromyelitis Optica | 4 | 2023 | 140 | 1.090 |
Why?
| | Immunologic Factors | 7 | 2025 | 260 | 0.880 |
Why?
| | Myelitis | 4 | 2020 | 107 | 0.850 |
Why?
| | Fatigue | 1 | 2025 | 366 | 0.760 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 5 | 2025 | 83 | 0.760 |
Why?
| | Cranial Nerve Diseases | 3 | 2017 | 44 | 0.710 |
Why?
| | Immunosuppressive Agents | 6 | 2024 | 838 | 0.670 |
Why?
| | Cerebral Veins | 1 | 2021 | 16 | 0.670 |
Why?
| | Central Nervous System Diseases | 1 | 2021 | 74 | 0.630 |
Why?
| | Cerebral Hemorrhage | 1 | 2021 | 125 | 0.620 |
Why?
| | Microvessels | 1 | 2021 | 97 | 0.610 |
Why?
| | Nervous System Diseases | 4 | 2019 | 286 | 0.590 |
Why?
| | Sarcoidosis | 1 | 2021 | 163 | 0.570 |
Why?
| | Venous Thrombosis | 1 | 2021 | 196 | 0.560 |
Why?
| | Child | 48 | 2026 | 22740 | 0.550 |
Why?
| | Adolescent | 45 | 2026 | 22577 | 0.540 |
Why?
| | Enterovirus Infections | 5 | 2020 | 173 | 0.540 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 4 | 2024 | 55 | 0.490 |
Why?
| | Movement Disorders | 1 | 2017 | 69 | 0.490 |
Why?
| | Muscular Diseases | 1 | 2017 | 109 | 0.490 |
Why?
| | Dimethyl Fumarate | 1 | 2016 | 12 | 0.470 |
Why?
| | Recurrence | 8 | 2025 | 1139 | 0.420 |
Why?
| | Rituximab | 4 | 2024 | 210 | 0.410 |
Why?
| | HLA-DRB1 Chains | 5 | 2023 | 110 | 0.380 |
Why?
| | Male | 53 | 2026 | 73012 | 0.380 |
Why?
| | Quality of Life | 1 | 2025 | 3211 | 0.380 |
Why?
| | Gene-Environment Interaction | 3 | 2023 | 180 | 0.380 |
Why?
| | Telomere | 2 | 2026 | 287 | 0.370 |
Why?
| | Demyelinating Diseases | 3 | 2023 | 84 | 0.370 |
Why?
| | Humans | 71 | 2026 | 145785 | 0.360 |
Why?
| | Genetic Predisposition to Disease | 6 | 2023 | 2399 | 0.340 |
Why?
| | Female | 51 | 2026 | 79045 | 0.340 |
Why?
| | Age of Onset | 9 | 2025 | 557 | 0.340 |
Why?
| | Case-Control Studies | 14 | 2026 | 3634 | 0.330 |
Why?
| | Paralysis | 3 | 2016 | 69 | 0.330 |
Why?
| | Epstein-Barr Virus Infections | 2 | 2022 | 101 | 0.330 |
Why?
| | Aging | 3 | 2026 | 1973 | 0.320 |
Why?
| | Epigenesis, Genetic | 2 | 2025 | 693 | 0.320 |
Why?
| | Magnetic Resonance Imaging | 9 | 2025 | 3916 | 0.310 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2025 | 992 | 0.300 |
Why?
| | Autoantibodies | 5 | 2024 | 1509 | 0.280 |
Why?
| | Vaccines | 1 | 2014 | 389 | 0.280 |
Why?
| | Central Nervous System Viral Diseases | 2 | 2020 | 78 | 0.280 |
Why?
| | Muscle Hypotonia | 2 | 2020 | 34 | 0.270 |
Why?
| | Aquaporin 4 | 3 | 2023 | 101 | 0.270 |
Why?
| | Neuromuscular Diseases | 2 | 2020 | 145 | 0.260 |
Why?
| | Treatment Outcome | 7 | 2025 | 11794 | 0.250 |
Why?
| | Fingolimod Hydrochloride | 2 | 2024 | 40 | 0.250 |
Why?
| | Sunlight | 2 | 2025 | 78 | 0.250 |
Why?
| | Neuropsychological Tests | 4 | 2025 | 1137 | 0.250 |
Why?
| | Cognition Disorders | 2 | 2022 | 544 | 0.250 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1791 | 0.250 |
Why?
| | Adjuvants, Immunologic | 2 | 2020 | 244 | 0.230 |
Why?
| | Interferon beta-1a | 1 | 2025 | 14 | 0.230 |
Why?
| | Gonadal Steroid Hormones | 2 | 2017 | 143 | 0.230 |
Why?
| | Telomere Homeostasis | 1 | 2025 | 33 | 0.230 |
Why?
| | Interferon-beta | 1 | 2025 | 92 | 0.220 |
Why?
| | Vaccination | 1 | 2014 | 1428 | 0.220 |
Why?
| | Menarche | 1 | 2025 | 53 | 0.210 |
Why?
| | Vitamin D | 2 | 2019 | 404 | 0.210 |
Why?
| | Transgender Persons | 3 | 2017 | 210 | 0.210 |
Why?
| | Enterovirus D, Human | 2 | 2016 | 87 | 0.200 |
Why?
| | Disease Progression | 4 | 2025 | 2865 | 0.200 |
Why?
| | Axons | 1 | 2025 | 204 | 0.190 |
Why?
| | Environmental Exposure | 2 | 2018 | 578 | 0.190 |
Why?
| | Risk Factors | 13 | 2025 | 10919 | 0.190 |
Why?
| | Follow-Up Studies | 5 | 2025 | 5428 | 0.190 |
Why?
| | Self Report | 2 | 2025 | 876 | 0.190 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2023 | 31 | 0.190 |
Why?
| | Adult | 18 | 2025 | 40882 | 0.180 |
Why?
| | Body Composition | 2 | 2017 | 693 | 0.180 |
Why?
| | Immunoglobulin G | 3 | 2022 | 892 | 0.180 |
Why?
| | Cognition | 3 | 2025 | 1271 | 0.170 |
Why?
| | Young Adult | 13 | 2025 | 14254 | 0.170 |
Why?
| | Parents | 3 | 2025 | 1407 | 0.160 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 1 | 2020 | 28 | 0.160 |
Why?
| | Muscle Weakness | 1 | 2020 | 92 | 0.150 |
Why?
| | Retrospective Studies | 11 | 2025 | 17330 | 0.150 |
Why?
| | Cohort Studies | 7 | 2025 | 6033 | 0.150 |
Why?
| | Lipids | 1 | 2025 | 707 | 0.150 |
Why?
| | Clinical Trials as Topic | 1 | 2024 | 1062 | 0.150 |
Why?
| | Enterovirus | 1 | 2019 | 83 | 0.140 |
Why?
| | Glatiramer Acetate | 1 | 2019 | 18 | 0.140 |
Why?
| | Heavy Ion Radiotherapy | 1 | 2018 | 1 | 0.140 |
Why?
| | Administration, Oral | 2 | 2025 | 867 | 0.140 |
Why?
| | Oxidoreductases | 1 | 2019 | 91 | 0.140 |
Why?
| | Education, Special | 1 | 2018 | 24 | 0.140 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2019 | 2181 | 0.140 |
Why?
| | Child, Preschool | 9 | 2024 | 11868 | 0.140 |
Why?
| | Disability Evaluation | 2 | 2020 | 311 | 0.140 |
Why?
| | Fluoxetine | 1 | 2018 | 56 | 0.140 |
Why?
| | Research Design | 1 | 2024 | 1139 | 0.140 |
Why?
| | Disease Susceptibility | 2 | 2017 | 344 | 0.140 |
Why?
| | United States | 12 | 2025 | 16126 | 0.130 |
Why?
| | Electromyography | 2 | 2017 | 419 | 0.130 |
Why?
| | B-Lymphocytes | 1 | 2023 | 872 | 0.130 |
Why?
| | Autoimmune Diseases | 1 | 2021 | 469 | 0.130 |
Why?
| | Neural Conduction | 1 | 2017 | 92 | 0.130 |
Why?
| | Atrophy | 1 | 2017 | 199 | 0.120 |
Why?
| | Longitudinal Studies | 4 | 2025 | 2968 | 0.120 |
Why?
| | Recovery of Function | 1 | 2020 | 716 | 0.120 |
Why?
| | Sodium Chloride, Dietary | 1 | 2016 | 31 | 0.120 |
Why?
| | Attitude | 1 | 2017 | 259 | 0.110 |
Why?
| | Depression | 1 | 2025 | 1559 | 0.110 |
Why?
| | Communicable Diseases | 1 | 2018 | 166 | 0.110 |
Why?
| | Developmental Disabilities | 1 | 2018 | 281 | 0.110 |
Why?
| | Dietary Fats | 1 | 2017 | 308 | 0.110 |
Why?
| | Encephalomyelitis, Acute Disseminated | 1 | 2015 | 11 | 0.110 |
Why?
| | Cross-Sectional Studies | 5 | 2026 | 5925 | 0.110 |
Why?
| | Marijuana Abuse | 1 | 2017 | 214 | 0.110 |
Why?
| | Prospective Studies | 7 | 2024 | 8078 | 0.110 |
Why?
| | Colorado | 4 | 2019 | 4556 | 0.110 |
Why?
| | Middle Aged | 9 | 2025 | 36309 | 0.110 |
Why?
| | Perception | 1 | 2017 | 378 | 0.110 |
Why?
| | Testosterone | 2 | 2017 | 416 | 0.110 |
Why?
| | Bone Remodeling | 1 | 2015 | 71 | 0.110 |
Why?
| | Paraplegia | 1 | 2014 | 60 | 0.100 |
Why?
| | Marijuana Smoking | 1 | 2017 | 249 | 0.100 |
Why?
| | Nuclear Proteins | 1 | 2019 | 740 | 0.100 |
Why?
| | Motor Neurons | 1 | 2016 | 236 | 0.100 |
Why?
| | Hypersensitivity | 1 | 2017 | 254 | 0.100 |
Why?
| | Bacterial Vaccines | 1 | 2014 | 63 | 0.100 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2014 | 132 | 0.100 |
Why?
| | CD40 Antigens | 1 | 2014 | 90 | 0.100 |
Why?
| | Infusions, Intravenous | 2 | 2025 | 428 | 0.100 |
Why?
| | Drug Monitoring | 1 | 2017 | 401 | 0.100 |
Why?
| | Aged | 6 | 2025 | 26217 | 0.090 |
Why?
| | MicroRNAs | 1 | 2019 | 686 | 0.090 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 498 | 0.090 |
Why?
| | Viral Vaccines | 1 | 2014 | 107 | 0.090 |
Why?
| | Antiviral Agents | 1 | 2018 | 769 | 0.090 |
Why?
| | Biomarkers | 5 | 2026 | 4302 | 0.090 |
Why?
| | Neuroimaging | 1 | 2014 | 300 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2933 | 0.090 |
Why?
| | T-Lymphocyte Subsets | 1 | 2014 | 420 | 0.090 |
Why?
| | Body Mass Index | 2 | 2017 | 2447 | 0.090 |
Why?
| | Herpesvirus 4, Human | 2 | 2022 | 172 | 0.080 |
Why?
| | Bone Density | 1 | 2015 | 487 | 0.080 |
Why?
| | Patient Outcome Assessment | 2 | 2023 | 130 | 0.080 |
Why?
| | Transcription Factors | 1 | 2019 | 1736 | 0.080 |
Why?
| | DNA Methylation | 2 | 2025 | 690 | 0.080 |
Why?
| | Ultraviolet Rays | 2 | 2023 | 385 | 0.080 |
Why?
| | Feeding Behavior | 1 | 2016 | 692 | 0.080 |
Why?
| | Death, Sudden | 1 | 2009 | 26 | 0.080 |
Why?
| | Diet | 1 | 2017 | 1278 | 0.070 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2010 | 159 | 0.070 |
Why?
| | Disease Outbreaks | 3 | 2019 | 419 | 0.070 |
Why?
| | Vena Cava, Inferior | 1 | 2009 | 83 | 0.070 |
Why?
| | Constriction, Pathologic | 1 | 2009 | 249 | 0.070 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2009 | 76 | 0.070 |
Why?
| | Testicular Neoplasms | 1 | 2009 | 111 | 0.070 |
Why?
| | Alleles | 2 | 2023 | 896 | 0.070 |
Why?
| | Genotype | 2 | 2023 | 1857 | 0.070 |
Why?
| | Sweden | 2 | 2017 | 115 | 0.060 |
Why?
| | Registries | 2 | 2025 | 2410 | 0.060 |
Why?
| | Risk | 2 | 2019 | 923 | 0.060 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 6085 | 0.060 |
Why?
| | Injections, Subcutaneous | 1 | 2025 | 170 | 0.060 |
Why?
| | Demyelinating Autoimmune Diseases, CNS | 1 | 2024 | 4 | 0.050 |
Why?
| | Injections, Intramuscular | 1 | 2025 | 146 | 0.050 |
Why?
| | Referral and Consultation | 2 | 2024 | 869 | 0.050 |
Why?
| | Injections | 1 | 2025 | 199 | 0.050 |
Why?
| | Haplotypes | 2 | 2019 | 500 | 0.050 |
Why?
| | Phosphatidylethanolamines | 1 | 2025 | 77 | 0.050 |
Why?
| | Influenza, Human | 1 | 2010 | 624 | 0.050 |
Why?
| | Neurofilament Proteins | 1 | 2025 | 79 | 0.050 |
Why?
| | Phosphatidylcholines | 1 | 2025 | 131 | 0.050 |
Why?
| | Brain | 3 | 2024 | 2969 | 0.050 |
Why?
| | Memory and Learning Tests | 1 | 2022 | 1 | 0.050 |
Why?
| | Azathioprine | 1 | 2022 | 44 | 0.050 |
Why?
| | Infant | 4 | 2020 | 10091 | 0.050 |
Why?
| | Logistic Models | 2 | 2018 | 2139 | 0.050 |
Why?
| | Demography | 1 | 2023 | 282 | 0.050 |
Why?
| | Genome-Wide Association Study | 2 | 2019 | 1430 | 0.040 |
Why?
| | Pandemics | 1 | 2010 | 1711 | 0.040 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2022 | 133 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 241 | 0.040 |
Why?
| | HLA Antigens | 1 | 2023 | 240 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2025 | 1330 | 0.040 |
Why?
| | Antigens, CD20 | 1 | 2020 | 34 | 0.040 |
Why?
| | Polyethylene Glycols | 1 | 2025 | 649 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2025 | 2028 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2024 | 309 | 0.040 |
Why?
| | Hospitalization | 1 | 2010 | 2461 | 0.040 |
Why?
| | Prevalence | 2 | 2017 | 2875 | 0.040 |
Why?
| | HIV Infections | 1 | 2015 | 3195 | 0.040 |
Why?
| | Stiff-Person Syndrome | 1 | 2019 | 14 | 0.040 |
Why?
| | HLA-A3 Antigen | 1 | 2019 | 6 | 0.040 |
Why?
| | HLA-B7 Antigen | 1 | 2019 | 7 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2022 | 821 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 42 | 0.040 |
Why?
| | Relative Biological Effectiveness | 1 | 2018 | 4 | 0.040 |
Why?
| | Glutamate Decarboxylase | 1 | 2019 | 165 | 0.040 |
Why?
| | International Agencies | 1 | 2018 | 30 | 0.040 |
Why?
| | Mathematical Concepts | 1 | 2018 | 35 | 0.040 |
Why?
| | Sex Factors | 1 | 2024 | 2110 | 0.030 |
Why?
| | Four-Dimensional Computed Tomography | 1 | 2018 | 38 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2023 | 780 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2018 | 141 | 0.030 |
Why?
| | Radiometry | 1 | 2018 | 56 | 0.030 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 88 | 0.030 |
Why?
| | Japan | 1 | 2018 | 149 | 0.030 |
Why?
| | Syndrome | 1 | 2019 | 381 | 0.030 |
Why?
| | Germany | 1 | 2018 | 138 | 0.030 |
Why?
| | Cancer Care Facilities | 1 | 2018 | 48 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2018 | 288 | 0.030 |
Why?
| | Cyproterone Acetate | 1 | 2017 | 2 | 0.030 |
Why?
| | Propensity Score | 1 | 2020 | 377 | 0.030 |
Why?
| | Waist-Hip Ratio | 1 | 2017 | 37 | 0.030 |
Why?
| | Central Nervous System | 1 | 2020 | 282 | 0.030 |
Why?
| | Radiation Oncology | 1 | 2018 | 82 | 0.030 |
Why?
| | Geography, Medical | 1 | 2017 | 11 | 0.030 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2018 | 149 | 0.030 |
Why?
| | Biomedical Research | 1 | 2024 | 719 | 0.030 |
Why?
| | Body Fat Distribution | 1 | 2017 | 46 | 0.030 |
Why?
| | Knowledge | 1 | 2017 | 57 | 0.030 |
Why?
| | Habits | 1 | 2017 | 52 | 0.030 |
Why?
| | Organ Size | 1 | 2018 | 461 | 0.030 |
Why?
| | Reading | 1 | 2018 | 135 | 0.030 |
Why?
| | Water Quality | 1 | 2017 | 35 | 0.030 |
Why?
| | California | 1 | 2019 | 473 | 0.030 |
Why?
| | Global Health | 1 | 2020 | 403 | 0.030 |
Why?
| | Waist Circumference | 1 | 2017 | 143 | 0.030 |
Why?
| | Tumor Burden | 1 | 2018 | 325 | 0.030 |
Why?
| | Diet Surveys | 1 | 2017 | 90 | 0.030 |
Why?
| | Anthropometry | 1 | 2017 | 206 | 0.030 |
Why?
| | Mendelian Randomization Analysis | 1 | 2017 | 58 | 0.030 |
Why?
| | Forecasting | 1 | 2018 | 390 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2017 | 277 | 0.030 |
Why?
| | Vegetables | 1 | 2017 | 162 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2019 | 318 | 0.030 |
Why?
| | Family | 1 | 2021 | 685 | 0.030 |
Why?
| | Consensus | 1 | 2018 | 479 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2018 | 259 | 0.030 |
Why?
| | North America | 1 | 2017 | 304 | 0.030 |
Why?
| | Binding Sites | 1 | 2019 | 1311 | 0.030 |
Why?
| | Focus Groups | 1 | 2018 | 572 | 0.030 |
Why?
| | Gender Identity | 1 | 2016 | 129 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 1001 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1083 | 0.030 |
Why?
| | Genetic Testing | 1 | 2017 | 483 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1547 | 0.030 |
Why?
| | Brain Stem | 1 | 2014 | 98 | 0.030 |
Why?
| | Estradiol | 1 | 2017 | 515 | 0.030 |
Why?
| | Air Pollution | 1 | 2017 | 315 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2019 | 2064 | 0.020 |
Why?
| | Self Efficacy | 1 | 2017 | 413 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2014 | 220 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2014 | 501 | 0.020 |
Why?
| | Cell Separation | 1 | 2014 | 306 | 0.020 |
Why?
| | Parkinson Disease | 1 | 2019 | 601 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1777 | 0.020 |
Why?
| | Muscle Strength | 1 | 2015 | 332 | 0.020 |
Why?
| | Acute Disease | 1 | 2014 | 1036 | 0.020 |
Why?
| | Animals | 1 | 2014 | 38106 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2014 | 1165 | 0.020 |
Why?
| | Autopsy | 1 | 2009 | 94 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1372 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 7134 | 0.020 |
Why?
| | Autoimmunity | 1 | 2014 | 933 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2009 | 688 | 0.020 |
Why?
| | Vascular Diseases | 1 | 2009 | 252 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 3170 | 0.010 |
Why?
| | Signal Transduction | 1 | 2019 | 5226 | 0.010 |
Why?
| | Asthma | 1 | 2017 | 1797 | 0.010 |
Why?
| | Age Factors | 1 | 2010 | 3346 | 0.010 |
Why?
|
|
Schreiner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|